0
0

Expanding Access to Low-Cost Generics Act of 2019

10/28/2022, 1:46 AM

Congressional Summary of S 3092

Expanding Access to Low-Cost Generics Act of 2019

This bill modifies the 180-day exclusivity period for certain generic drug manufacturers.

Current Status of Bill S 3092

Bill S 3092 is currently in the status of Bill Introduced since December 18, 2019. Bill S 3092 was introduced during Congress 116 and was introduced to the Senate on December 18, 2019.  Bill S 3092's most recent activity was Read twice and referred to the Committee on Health, Education, Labor, and Pensions. as of December 18, 2019

Bipartisan Support of Bill S 3092

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill S 3092

Primary Policy Focus

Health

Potential Impact Areas

- Civil actions and liability
- Drug safety, medical device, and laboratory regulation
- Intellectual property
- Prescription drugs

Alternate Title(s) of Bill S 3092

Expanding Access to Low-Cost Generics Act of 2019
Expanding Access to Low-Cost Generics Act of 2019
A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period, and for other purposes.

Comments